Across TCGA pan-cancer cohorts, ZNF564 mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of ZNF564’s most consistent transcriptional readouts.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ZNF564 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ZNF564 is over-expressed in tumor.
LSCC are the cancer types where ZNF564 tumor–normal differential expression is most reproducible.